Finally, there’s a bit of good news in the fight against COVID-19. The Food and Drug Administration issued an “emergency use authorization” for remdesivir, an anti-viral drug that could help coronavirus patients recover faster. The medicine isn’t a silver bullet, but it’s the first therapy that has shown success in clinical trials. Yet one self-styled […]
Author Archives: Paul Langley
Paul C. Langley is a professor at the University of Minnesota, director of Maimon Research and research director of the Institute for Patient Access.